Friday, July 10, 2026

pharma · Systemic Lupus Erythematosus · Lupus Erythematosus, Systemic

Serana Europe

Serana Europe clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Pessin, DE HQ
2014 Founded
20 Employees
EMA registrant Type
Company details
Status
Public
HQ
Pessin, DE
Founded
2014
Employees
20
Programs
8
Drugs
8
Patents
0
Intelligence · Clinical Programs

Serana Europe projects

2 ClinicalTrials.gov programs sponsored by Serana Europe.

Serana Europe has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Avelumab

    Serono Europe Limited

    First Line Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial
  2. Xevinapant (Debio 1143)

    Serono Europe Limited

    Squamous Cell Carcinoma of the Head and Neck

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Serana Europe have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.